Parabilis Medicines, Inc.(PBLS)

Biotechnology · Cambridge, MA

$28.86-0.67 (-2.27%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T20:13:01.019Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:13:01.019Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 3,364,053,490
Total debt · period ending 2026-06-30: 47,512,000
Cash · period ending 2026-06-30: 1,087,060,000
TTM operating income · period ending 2026-06-30: N/A

FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PBLS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

PBLS Competitors' EV/EBIT Ratio

PBLS

Parabilis Medicines, Inc.

Current

Market Cap

$3.36B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACAD

Acadia Pharmaceuticals Inc.

vs PBLS

Market Cap

$3.38B

EV/EBIT Ratio

35.54x

TTM Avg

33.32x

3Y Avg

35.69x

5Y Avg

35.69x

VKTX

Viking Therapeutics, Inc.

vs PBLS

Market Cap

$3.31B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDNA

CareDx, Inc

vs PBLS

Market Cap

$3.30B

EV/EBIT Ratio

N/A

TTM Avg

18.58x

3Y Avg

18.58x

5Y Avg

18.58x

PLSE

Pulse Biosciences, Inc.

vs PBLS

Market Cap

$3.44B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CELC

Celcuity Inc.

vs PBLS

Market Cap

$3.47B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs PBLS

Market Cap

$3.48B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRTC

iRhythm Technologies, Inc.

vs PBLS

Market Cap

$3.52B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XENE

Xenon Pharmaceuticals Inc.

vs PBLS

Market Cap

$3.54B

EV/EBIT Ratio

N/A

TTM Avg

12.29x

3Y Avg

12.23x

5Y Avg

12.23x

TARS

Tarsus Pharmaceuticals, Inc.

vs PBLS

Market Cap

$3.19B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Parabilis Medicines, Inc. (PBLS)	$3.36B	N/A	N/A	N/A	N/A
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.38B	35.54x	33.32x	35.69x	35.69x
Viking Therapeutics, Inc. (VKTX)vs ›	$3.31B	N/A	N/A	N/A	N/A
CareDx, Inc (CDNA)vs ›	$3.30B	N/A	18.58x	18.58x	18.58x
Pulse Biosciences, Inc. (PLSE)vs ›	$3.44B	N/A	N/A	N/A	N/A
Celcuity Inc. (CELC)vs ›	$3.47B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.48B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.52B	N/A	N/A	N/A	N/A
Xenon Pharmaceuticals Inc. (XENE)vs ›	$3.54B	N/A	12.29x	12.23x	12.23x
Tarsus Pharmaceuticals, Inc. (TARS)vs ›	$3.19B	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

PBLS EV/EBIT Ratio Metrics

PBLS Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics